OA12278A - Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof. - Google Patents

Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof. Download PDF

Info

Publication number: OA12278A
Authority: OA; OAPI
Prior art keywords: tank; bacteria; omv; serogroup; vaccine
Prior art date: 2000-06-02

Application number

OA1200200362A

Other languages

English (en)

Inventor

Audun Aase

Kari Harbak

Lisbeth Meyer Naess

Karin Nord

Einar Rosenqvist

Original Assignee

Statens Inst For Folkehelse

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-02

Filing date

2001-06-05

Publication date

2006-05-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19911219&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA12278(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-06-05 Application filed by Statens Inst For Folkehelse filed Critical Statens Inst For Folkehelse

2006-05-11 Publication of OA12278A publication Critical patent/OA12278A/en

Links

229960005486 vaccine Drugs 0.000 title claims abstract description 68
238000000034 method Methods 0.000 title claims abstract description 45
239000012528 membrane Substances 0.000 title claims abstract description 38
230000008569 process Effects 0.000 title claims abstract description 24
201000010099 disease Diseases 0.000 title claims abstract description 8
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 8
241000921898 Neisseria meningitidis serogroup A Species 0.000 title claims description 3
238000004519 manufacturing process Methods 0.000 title description 9
241000894006 Bacteria Species 0.000 claims description 45
239000000725 suspension Substances 0.000 claims description 29
230000001580 bacterial effect Effects 0.000 claims description 28
102000004169 proteins and genes Human genes 0.000 claims description 27
108090000623 proteins and genes Proteins 0.000 claims description 27
239000000872 buffer Substances 0.000 claims description 25
239000003599 detergent Substances 0.000 claims description 22
238000001914 filtration Methods 0.000 claims description 20
238000009295 crossflow filtration Methods 0.000 claims description 19
239000008188 pellet Substances 0.000 claims description 16
238000000605 extraction Methods 0.000 claims description 14
239000011148 porous material Substances 0.000 claims description 13
238000003756 stirring Methods 0.000 claims description 13
239000003613 bile acid Substances 0.000 claims description 12
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 11
238000000703 high-speed centrifugation Methods 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
101710116435 Outer membrane protein Proteins 0.000 claims description 7
239000002671 adjuvant Substances 0.000 claims description 7
208000015181 infectious disease Diseases 0.000 claims description 7
239000006285 cell suspension Substances 0.000 claims description 4
239000000969 carrier Substances 0.000 claims description 3
239000003381 stabilizer Substances 0.000 claims description 3
230000003247 decreasing effect Effects 0.000 claims description 2
239000003937 drug carrier Substances 0.000 claims description 2
238000005374 membrane filtration Methods 0.000 claims description 2
235000018102 proteins Nutrition 0.000 claims 2
235000004252 protein component Nutrition 0.000 claims 1
241000588650 Neisseria meningitidis Species 0.000 abstract description 7
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 43
229940009976 deoxycholate Drugs 0.000 description 40
241000699670 Mus sp. Species 0.000 description 27
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 17
229930006000 Sucrose Natural products 0.000 description 17
239000002158 endotoxin Substances 0.000 description 17
229920006008 lipopolysaccharide Polymers 0.000 description 17
239000002609 medium Substances 0.000 description 17
239000005720 sucrose Substances 0.000 description 17
210000004027 cell Anatomy 0.000 description 16
238000005119 centrifugation Methods 0.000 description 15
229920001282 polysaccharide Polymers 0.000 description 14
239000005017 polysaccharide Substances 0.000 description 14
150000004676 glycans Chemical class 0.000 description 13
230000002779 inactivation Effects 0.000 description 13
230000000844 anti-bacterial effect Effects 0.000 description 12
239000006228 supernatant Substances 0.000 description 12
238000000746 purification Methods 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
201000009906 Meningitis Diseases 0.000 description 10
239000000463 material Substances 0.000 description 10
230000000890 antigenic effect Effects 0.000 description 8
230000012010 growth Effects 0.000 description 8
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 7
239000000427 antigen Substances 0.000 description 7
102000036639 antigens Human genes 0.000 description 7
108091007433 antigens Proteins 0.000 description 7
238000012360 testing method Methods 0.000 description 7
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 5
241000699666 Mus <mouse, genus> Species 0.000 description 5
230000002458 infectious effect Effects 0.000 description 5
238000002955 isolation Methods 0.000 description 5
230000002147 killing effect Effects 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000011734 sodium Substances 0.000 description 5
238000012546 transfer Methods 0.000 description 5
239000007983 Tris buffer Substances 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229960003964 deoxycholic acid Drugs 0.000 description 4
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Chemical class C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000012544 monitoring process Methods 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 4
229960004906 thiomersal Drugs 0.000 description 4
-1 Bile acid anions Chemical class 0.000 description 3
101710164702 Major outer membrane protein Proteins 0.000 description 3
241000040340 Oat mosaic virus Species 0.000 description 3
238000004458 analytical method Methods 0.000 description 3
210000000941 bile Anatomy 0.000 description 3
230000008859 change Effects 0.000 description 3
230000004087 circulation Effects 0.000 description 3
239000012141 concentrate Substances 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
238000003119 immunoblot Methods 0.000 description 3
230000002163 immunogen Effects 0.000 description 3
230000005847 immunogenicity Effects 0.000 description 3
239000007788 liquid Substances 0.000 description 3
208000037941 meningococcal disease Diseases 0.000 description 3
239000000693 micelle Substances 0.000 description 3
150000003904 phospholipids Chemical class 0.000 description 3
229940031937 polysaccharide vaccine Drugs 0.000 description 3
238000011045 prefiltration Methods 0.000 description 3
239000000047 product Substances 0.000 description 3
238000005086 pumping Methods 0.000 description 3
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
239000006150 trypticase soy agar Substances 0.000 description 3
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Chemical class OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 2
GNFTZDOKVXKIBK-UHFFFAOYSA-N 3-(2-methoxyethoxy)benzohydrazide Chemical compound COCCOC1=CC=CC(C(=O)NN)=C1 GNFTZDOKVXKIBK-UHFFFAOYSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
208000002109 Argyria Diseases 0.000 description 2
108010060123 Conjugate Vaccines Proteins 0.000 description 2
102000004190 Enzymes Human genes 0.000 description 2
108090000790 Enzymes Proteins 0.000 description 2
230000005526 G1 to G0 transition Effects 0.000 description 2
241000588653 Neisseria Species 0.000 description 2
241000838698 Togo Species 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000008272 agar Substances 0.000 description 2
230000002776 aggregation Effects 0.000 description 2
238000004220 aggregation Methods 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
239000012736 aqueous medium Substances 0.000 description 2
238000003556 assay Methods 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000008901 benefit Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
229940031670 conjugate vaccine Drugs 0.000 description 2
230000009089 cytolysis Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
238000010790 dilution Methods 0.000 description 2
239000012895 dilution Substances 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
238000010494 dissociation reaction Methods 0.000 description 2
230000005593 dissociations Effects 0.000 description 2
238000005187 foaming Methods 0.000 description 2
238000002649 immunization Methods 0.000 description 2
230000007774 longterm Effects 0.000 description 2
238000003760 magnetic stirring Methods 0.000 description 2
229940100892 mercury compound Drugs 0.000 description 2
150000002731 mercury compounds Chemical class 0.000 description 2
230000002906 microbiologic effect Effects 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052760 oxygen Inorganic materials 0.000 description 2
230000003019 stabilising effect Effects 0.000 description 2
239000012137 tryptone Substances 0.000 description 2
238000002604 ultrasonography Methods 0.000 description 2
238000005303 weighing Methods 0.000 description 2
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Chemical class OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
241000969130 Atthis Species 0.000 description 1
FGUUSXIOTUKUDN-IBGZPJMESA-N C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 Chemical compound C1(=CC=CC=C1)N1C2=C(NC([C@H](C1)NC=1OC(=NN=1)C1=CC=CC=C1)=O)C=CC=C2 FGUUSXIOTUKUDN-IBGZPJMESA-N 0.000 description 1
241001493150 Capim virus Species 0.000 description 1
239000004380 Cholic acid Chemical class 0.000 description 1
241000134884 Ericales Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
101710105759 Major outer membrane porin Proteins 0.000 description 1
108010052285 Membrane Proteins Proteins 0.000 description 1
206010027202 Meningitis bacterial Diseases 0.000 description 1
208000034762 Meningococcal Infections Diseases 0.000 description 1
241000790101 Myriopus Species 0.000 description 1
241000588677 Neisseria meningitidis serogroup B Species 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
239000002033 PVDF binder Substances 0.000 description 1
102000017033 Porins Human genes 0.000 description 1
108010013381 Porins Proteins 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
230000004520 agglutination Effects 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000027645 antigenic variation Effects 0.000 description 1
201000009904 bacterial meningitis Diseases 0.000 description 1
239000006161 blood agar Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
RUDATBOHQWOJDD-BSWAIDMHSA-N chenodeoxycholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-BSWAIDMHSA-N 0.000 description 1
229960001091 chenodeoxycholic acid Drugs 0.000 description 1
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
229960002471 cholic acid Drugs 0.000 description 1
235000019416 cholic acid Nutrition 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000012258 culturing Methods 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
KSCFJBIXMNOVSH-UHFFFAOYSA-N dyphylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1N(CC(O)CO)C=N2 KSCFJBIXMNOVSH-UHFFFAOYSA-N 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000002360 explosive Substances 0.000 description 1
239000011536 extraction buffer Substances 0.000 description 1
239000012467 final product Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
229910001679 gibbsite Inorganic materials 0.000 description 1
239000003102 growth factor Substances 0.000 description 1
231100001261 hazardous Toxicity 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
230000006054 immunological memory Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
230000002452 interceptive effect Effects 0.000 description 1
230000009545 invasion Effects 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical group O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical class C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
238000013507 mapping Methods 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
230000015654 memory Effects 0.000 description 1
230000003446 memory effect Effects 0.000 description 1
229960005037 meningococcal vaccines Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
238000002156 mixing Methods 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000013421 nuclear magnetic resonance imaging Methods 0.000 description 1
229920001542 oligosaccharide Polymers 0.000 description 1
150000002482 oligosaccharides Chemical class 0.000 description 1
229960005030 other vaccine in atc Drugs 0.000 description 1
239000006174 pH buffer Substances 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
239000013618 particulate matter Substances 0.000 description 1
230000008506 pathogenesis Effects 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
229920002981 polyvinylidene fluoride Polymers 0.000 description 1
238000013404 process transfer Methods 0.000 description 1
238000012545 processing Methods 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000019624 protein content Nutrition 0.000 description 1
229940023143 protein vaccine Drugs 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
239000002904 solvent Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
238000003860 storage Methods 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000009210 therapy by ultrasound Methods 0.000 description 1
230000007704 transition Effects 0.000 description 1
238000002525 ultrasonication Methods 0.000 description 1
BHQCQFFYRZLCQQ-UTLSPDKDSA-N ursocholic acid Chemical class C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical class C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
229960001661 ursodiol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicinal Preparation (AREA)

OA1200200362A 2000-06-02 2001-06-05 Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof. OA12278A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
NO20002828A NO20002828D0 (no)	2000-06-02	2000-06-02	Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav

Publications (1)

Publication Number	Publication Date
OA12278A true OA12278A (en)	2006-05-11

Family

ID=19911219

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200200362A OA12278A (en)	2000-06-02	2001-06-05	Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof.

Country Status (10)

Country	Link
US (1)	US20040131642A1 (de)
EP (1)	EP1286696B1 (de)
AP (1)	AP1690A (de)
AT (1)	ATE345143T1 (de)
AU (1)	AU2001264427A1 (de)
CA (1)	CA2410652A1 (de)
DE (1)	DE60124538D1 (de)
NO (1)	NO20002828D0 (de)
OA (1)	OA12278A (de)
WO (1)	WO2001091788A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2270173E (pt)	1999-05-19	2016-03-28	Glaxosmithkline Biologicals Sa	Composições de neisseria de combinação
GB9928196D0 (en)	1999-11-29	2000-01-26	Chiron Spa	Combinations of B, C and other antigens
WO2002009643A2 (en)	2000-07-27	2002-02-07	Children's Hospital & Research Center At Oakland	Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0130123D0 (en)	2001-12-17	2002-02-06	Microbiological Res Agency	Outer membrane vesicle vaccine and its preparation
GB0220194D0 (en)	2002-08-30	2002-10-09	Chiron Spa	Improved vesicles
WO2004046177A2 (en)	2002-11-15	2004-06-03	Chiron Srl	Unexpected surface proteins in neisseria meningitidis
CU23313A1 (es) *	2002-11-27	2008-09-25	Inst Finlay Ct De Investigacia	Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
AU2003288558A1 (en) *	2002-12-16	2004-07-09	Nasjonalt Folkehelseinstitutt	Meningococcal vaccine based on outer membrane proteins porb2 and pora
GB0316560D0 (en)	2003-07-15	2003-08-20	Chiron Srl	Vesicle filtration
CU23377A1 (es) *	2003-11-04	2009-05-28	Ct De Ingenieria Genetica Y Biotecnologia	Metodo para la incorporacion de antigenos en vesiculas de membrana externa de bacterias y formulaciones resultantes
GB0416120D0 (en)	2004-07-19	2004-08-18	Health Prot Agency	Stable compositions containing OMV's
GB0419627D0 (en)	2004-09-03	2004-10-06	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en)	2004-10-29	2004-12-01	Chiron Srl	Immunogenic bacterial vesicles with outer membrane proteins
ES2616294T3 (es)	2005-01-27	2017-06-12	Children's Hospital & Research Center At Oakland	Vacunas de vesículas basadas en GNA1870 para protección de amplio espectro contra enfermedades provocadas por Neisseria meningitidis
WO2007139746A1 (en)	2006-05-22	2007-12-06	Biovest International Inc.	Rotary actuator valve for a cell culture system
MX340096B (es)	2007-10-19	2016-06-27	Glaxosmithkline Biologicals Sa	Formulaciones de vacuna meningococica.
BRPI0907843A2 (pt)	2008-02-21	2015-08-04	Novartis Ag	Polipeptídeos de fhbp menigocócicos
PT2268618E (pt)	2008-03-03	2015-10-12	Novartis Ag	Compostos e composições moduladores da actividade tlr
WO2009158142A1 (en)	2008-05-30	2009-12-30	The U.S.A., As Represented By The Secretary Of The Army, On Behalf Of Walter Reed Army	Meningococcal multivalent native outer membrane vesicle vaccine, methods of making and use thereof
GB0822634D0 (en)	2008-12-11	2009-01-21	Novartis Ag	Meningitis vaccines
JP2012512240A (ja)	2008-12-17	2012-05-31	ノバルティスアーゲー	ヘモグロビン受容体を含む髄膜炎菌ワクチン
WO2010144734A1 (en)	2009-06-10	2010-12-16	Novartis Ag	Benzonaphthyridine-containing vaccines
JP2013503148A (ja)	2009-08-27	2013-01-31	ノバルティスアーゲー	アルミニウム、オリゴヌクレオチドおよびポリカチオンを含むアジュバント
JP2013502918A (ja)	2009-08-27	2013-01-31	ノバルティスアーゲー	髄膜炎菌ｆＨＢＰ配列を含むハイブリッドポリペプチド
JO3257B1 (ar)	2009-09-02	2018-09-16	Novartis Ag	مركبات وتركيبات كمعدلات لفاعلية tlr
JP5988492B2 (ja)	2009-09-02	2016-09-07	ノバルティスアーゲー	Ｔｌｒ活性モジュレーターを含む免疫原性組成物
GB0917003D0 (en)	2009-09-28	2009-11-11	Novartis Vaccines Inst For Global Health Srl	Purification of bacterial vesicles
WO2011039631A2 (en)	2009-09-30	2011-04-07	Novartis Ag	Expression of meningococcal fhbp polypeptides
US20130022633A1 (en)	2009-10-27	2013-01-24	University Of Florence	MENINGOCOCCAL fHBP POLYPEPTIDES
WO2011057148A1 (en)	2009-11-05	2011-05-12	Irm Llc	Compounds and compositions as tlr-7 activity modulators
BR112012014624A8 (pt)	2009-12-15	2017-12-26	Novartis Ag	suspensão homogênea de compostos de imunopotenciação e usos dos destes
MX2012010609A (es)	2010-03-18	2012-10-03	Novartis Ag	Vacunas adyuvadas para meningococos serogrupo b.
EP2549990A1 (de)	2010-03-23	2013-01-30	Irm Llc	Verbindungen (cysteinbasierte lipopeptide) und zusammensetzungen als tlr2-agonisten zur behandlung von infektionen, entzündungen, atemwegserkrankungen etc.
ES2759484T3 (es)	2010-09-10	2020-05-11	Glaxosmithkline Biologicals Sa	Meningococo que sobreexpresa NadA y/o NHBA y vesículas de la membrana externa derivadas del mismo
EP2707009A1 (de)	2011-05-12	2014-03-19	Novartis AG	Antipyretika zur verbesserung der verträglichkeit von impfstoffen auf vesikelbasis
WO2012171030A2 (en)	2011-06-10	2012-12-13	Biovest International, Inc.	Method and apparatus for antibody production and purification
AU2013214105A1 (en)	2012-02-02	2014-07-24	Novartis Ag	Promoters for increased protein expression in meningococcus
US10598666B2 (en)	2012-03-08	2020-03-24	Glaxosmithkline Biologicals Sa	In vitro potency assay for protein-based meningococcal vaccines
EP2861247B1 (de)	2012-06-14	2020-12-09	GlaxoSmithKline Biologicals SA	Impfstoffe gegen serogruppe-x-meningokokken
CA2920957A1 (en)	2012-08-28	2014-03-06	Biovest International, Inc.	Biomanufacturing suite and methods for large-scale production of cells, viruses, and biomolecules
RU2015106930A (ru)	2012-09-06	2016-10-20	Новартис Аг	Комбинированные вакцины с менингококком серогруппы в и к/д/с
MX363529B (es)	2012-09-18	2019-03-27	Novartis Ag	Vesículas de membrana externa.
CA2900454A1 (en)	2013-02-07	2014-08-14	Glaxosmithkline Biologicals Sa	Pharmaceutical compositions comprising vesicles
KR102779223B1 (ko)	2014-02-28	2025-03-07	글락소스미스클라인 바이오로지칼즈 에스.에이.	변형된 수막구균 fhbp 폴리펩티드
US11066453B2 (en)	2015-05-18	2021-07-20	Biomvis Srl	Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
US12109259B2 (en)	2016-09-02	2024-10-08	Glaxosmithkline Biologicals Sa	Vaccines for Neisseria gonorrhoeae
EP3607967A1 (de)	2018-08-09	2020-02-12	GlaxoSmithKline Biologicals S.A.	Modifizierte meningokokken fhbp polypeptide
AU2019376832B2 (en)	2018-11-06	2024-01-25	Glaxosmithkline Biologicals Sa	Immunogenic compositions
CN112410239B (zh) *	2019-08-22	2023-03-24	四川大学	细菌膜囊泡及其制备方法与应用
WO2025175304A2 (en)	2024-02-16	2025-08-21	Sanofi Pasteur Inc.	Process for the preparation of deoxycholic acid
WO2025183190A1 (ja) *	2024-02-28	2025-09-04	株式会社ヤクルト本社	グラム陽性菌の膜小胞の製造方法及びその膜小胞の利用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2631035B2 (ja) *	1991-03-12	1997-07-16	アメリカ合衆国	多糖類−タンパク質複合体
US5324442A (en) *	1992-06-16	1994-06-28	Kansas State University Research Foundation	Fermentation process for the production of calcium magnesium road deicer
GB9726398D0 (en) *	1997-12-12	1998-02-11	Isis Innovation	Polypeptide and coding sequences
ATE446368T1 (de) *	1998-01-14	2009-11-15	Novartis Vaccines & Diagnostic	Antigene aus neisseria meningitidis
GB9820003D0 (en) *	1998-09-14	1998-11-04	Smithkline Beecham Biolog	Novel compounds
CA2359492A1 (en) *	1999-01-15	2000-07-20	Smithkline Beecham Biologicals S.A.	Neisseria meningitidis antigen
AU756832B2 (en) *	1999-02-22	2003-01-23	Ncsrt, Inc.	Purification of biological substances
GB9918319D0 (en) *	1999-08-03	1999-10-06	Smithkline Beecham Biolog	Vaccine composition
WO2002009643A2 (en) *	2000-07-27	2002-02-07	Children's Hospital & Research Center At Oakland	Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) *	2001-02-08	2001-03-28	Smithkline Beecham Biolog	Vaccine composition
GB0024200D0 (en) *	2000-10-03	2000-11-15	Smithkline Beecham Sa	Component vaccine

2000
- 2000-06-02 NO NO20002828A patent/NO20002828D0/no unknown
2001
- 2001-06-05 AU AU2001264427A patent/AU2001264427A1/en not_active Abandoned
- 2001-06-05 AT AT01938851T patent/ATE345143T1/de not_active IP Right Cessation
- 2001-06-05 CA CA002410652A patent/CA2410652A1/en not_active Abandoned
- 2001-06-05 WO PCT/NO2001/000232 patent/WO2001091788A1/en not_active Ceased
- 2001-06-05 OA OA1200200362A patent/OA12278A/en unknown
- 2001-06-05 EP EP01938851A patent/EP1286696B1/de not_active Revoked
- 2001-06-05 AP APAP/P/2002/002681A patent/AP1690A/en active
- 2001-06-05 DE DE60124538T patent/DE60124538D1/de not_active Expired - Lifetime
- 2001-06-05 US US10/296,212 patent/US20040131642A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2001091788A1 (en)	2001-12-06
NO20002828D0 (no)	2000-06-02
DE60124538D1 (de)	2006-12-28
AP2002002681A0 (en)	2002-12-31
ATE345143T1 (de)	2006-12-15
AP1690A (en)	2006-12-11
EP1286696B1 (de)	2006-11-15
EP1286696A1 (de)	2003-03-05
US20040131642A1 (en)	2004-07-08
CA2410652A1 (en)	2001-12-06
AU2001264427A1 (en)	2001-12-11

Publication	Publication Date	Title
OA12278A (en)	2006-05-11	Outer membrane vesicle vaccine against disease caused by neisseria meningitidis serogroup A and process for the production thereof.
EP1644035B1 (de)	2011-08-24	Ultrafiltration und ultracentrifugation zur preparation von membran-vesikeln (omv)
RU2325184C2 (ru)	2008-05-27	Улучшенные везикулы наружной мембраны бактерий
RU2607021C2 (ru)	2017-01-10	Способ бездетергентного получения везикул наружной мембраны грамотрицательной бактерии
US6921537B2 (en)	2005-07-26	Preparation and uses of los-depleted outer membrane proteins of gram-negative cocci
TW200817034A (en)	2008-04-16	Vaccine
TW200408406A (en)	2004-06-01	Vaccine
EA023470B1 (ru)	2016-06-30	Новые составы, стабилизирующие иммуногенные композиции и ингибирующие их осаждение
JP2005514388A (ja)	2005-05-19	グラム陰性菌由来の外膜小胞およびワクチンとしての使用
JP2006506467A5 (de)	2006-09-14
EP2988779B1 (de)	2020-05-13	Bakterienmutanten zur herstellung von allgemeinen modulen für membranantigene
US7820185B2 (en)	2010-10-26	Stable compositions containing OMVs
EP2929894B1 (de)	2018-02-21	Impfungsadjuvans, herstellung und impfstoffe damit
Jiskoot et al.	1986	Immunogenic activity of gonococcal protein I in mice with three different lipoidal adjuvants delivered in liposomes and in complexes
WO2004054611A1 (en)	2004-07-01	Meningococcal vaccine based on outer membrane proteins porb2 and pora
EP0090660A2 (de)	1983-10-05	Neisseria Gonorrhöe Vakzin
RU2005102587A (ru)	2005-09-10	Вакцинная композиция, содержащая трансферрин-связывающий белок и hsf из грамотрицательных бактерий